About the Authors

Itziar Montalvo

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Alfonso Gutiérrez-Zotes

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Marta Creus

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Rosa Monseny

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Laura Ortega

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Joan Franch

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Stephen M. Lawrie

Affiliation Division of Psychiatry, Kennedy Tower, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, United Kingdom

Rebecca M. Reynolds

Affiliation Endocrinology Unit, University/BHF Centre for Cardiovascular Sciences, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom

Elisabet Vilella

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Javier Labad

labadj@peremata.com

Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain

Competing Interests

SML has received financial support from Pfizer (formerly Wyeth) in relation to imaging studies of people with schizophrenia and bipolar disorder. SML has done consultancy work for Roche Pharmaceuticals in connection with a possible new treatment for schizophrenia. SML has also received honoraria for lectures, chairing meetings, and consultancy work from Janssen in connection with brain imaging and therapeutic initiatives for psychosis. JL has received honoraria for lectures from Janssen. IM, AGZ, MC, LO, RM, JF, EV and RMR have no biomedical financial interests or potential conflicts of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: JL AGZ RMR SML. Performed the experiments: IM MC JF LO RM. Analyzed the data: JL IM. Contributed reagents/materials/analysis tools: RMR EV. Wrote the paper: IM RMR EV JL.